金黄色葡萄球菌IsdB表位蛋白与HBc蛋白融合表达

doi:10.13481/j.1671-587x.20150212

吉林大学学报(医学版) ›› 2015, Vol. 41 ›› Issue (02): 269-274.doi: 10.13481/j.1671-587x.20150212

金黄色葡萄球菌IsdB表位蛋白与HBc蛋白融合表达

白靓¹, 成岩², 徐芳菲³, 刘燕¹, 张树军¹, 曹瑞珍¹

1. 内蒙古民族大学生命科学学院生物化学与分子生物学教研室, 内蒙古通辽 028000;
2. 内蒙古民族大学医学院病原生物学与免疫学教研室, 内蒙古通辽 028000;
3. 吉林省集安益盛药业股份有限公司, 吉林集安 134200

收稿日期:2014-11-24 出版日期:2015-03-28 发布日期:2015-04-04
通讯作者: 白靓, 副教授(Tel:0475-8314657, E-mail:jilinbl@126.com) E-mail:jilinbl@126.com
作者简介:白靓(1981-), 女, 吉林省敦化市人, 副教授, 医学博士, 主要从事分子免疫学方面的研究。
基金资助:
内蒙古自治区科技厅自然科学基金资助课题(2011BS0401);内蒙古民族大学博士科研启动基金资助课题(BS280)

Fusion expression of Staphylococcus aureus IsdB epitope protein and HBc protein

BAI Liang¹, CHENG Yan², XU Fangfei³, LIU Yan¹, ZHANG Shujun¹, CAO Ruizhen¹

1. Department of Biochemistry and Molecular Biology, School of Life Science, Inner Mongolia University for Nationalities, Tongliao 028000, China;
2. Department of Immunology and Microbiology, School of Medical Sciences, Inner Mongolia University for Nationalities, Tongliao 028000, China;
3. Ji'an Yisheng Pharmaceutical Co.Ltd., Jilin Provice, Ji'an 134200, China

Received:2014-11-24 Online:2015-03-28 Published:2015-04-04

摘要/Abstract

摘要：

目的:采用大肠杆菌表达HBc-IsdB_50-285融合蛋白,探讨其在原核表达系统中的表达效果。方法:设计并克隆HBc-IsdB_50-285融合基因片段,构建表达质粒pET-28-HBc-IsdB_50-285,并转化入E.coli BL21,异丙基硫代半乳糖苷(IPTG)诱导蛋白表达。SDS-PAGE分析蛋白可溶性及相对分子质量;BCA法测蛋白浓度;采用免疫接种法检测重组蛋白的免疫活性。40只小鼠随机分为rIsdB+adjuvant组、HBc-IsdB_50-285+adjuvant组、HBc-IsdB_50-285组和PBS组,每组10只,间接ELISA法检测小鼠特异性IgG效价值,采用金黄色葡萄球菌Newman株对免疫后小鼠攻毒,检测各组小鼠重组蛋白免疫保护效果。结果:表达质粒pET-28-HBc-IsdB_50-285经测序及酶切鉴定证明构建正确;SDS-PAGE分析,重组蛋白以部分可溶形式存在于培养上清中,相对分子质量约为44 000,亲和纯化后蛋白质水平为1.0 g·L^-1。ELISA检测,使用rIsdB蛋白包被酶标板,HBc-IsdB_50-285+adjuvan组小鼠血清特异性抗体滴度的效价值低于rIsdB+adjuvant组(P<0.01);使用HBc-IsdB_50-285蛋白包被酶标板,HBc-IsdB_50-285+adjuvant组的小鼠血清特异性抗体滴度的效价值高于rIsdB+adjuvant和HBc-IsdB_50-285组。攻毒实验,HBc-IsdB_50-285+adjuvant组小鼠对金黄色葡萄球菌免疫保护率低于rIsdB+adjuvant组,但差异无统计学意义(P>0.05);且其与HBc-IsdB_50-285未添加佐剂组比较差异也无统计学意义(P>0.05);与PBS组比较,HBc-IsdB_50-285+adjuvant组小鼠对金黄色葡萄球免疫保护率升高(P<0.01),HBc-IsdB_50-285组小鼠对金黄色葡萄球菌攻毒保护率亦升高(P<0.05)。结论:HBc-IsdB_50-285原核表达载体构建成功;在大肠杆菌中成功表达具有较好生物活性的HBc-IsdB_50-285融合蛋白。

关键词: 金黄色葡萄球菌, 乙型肝炎病毒核心蛋白, 铁调节表面决定因子B, 表位

Abstract:

Objective To construct the E.coli expressiom system of the HBc-IsdB_50-285 fusion protein, and to explore the expression efficacy of the HBc-IsdB_50-285 fusion protein in prokaryotic system.Methods HBc-IsdB_50-285 fusion gene fragment was designed and cloned,and the expression vector pET-28-HBc-IsdB_50-285 was construct and transformed into E.coli BL21,the expression of protein was inducted by IPTG. The solubility of protein and its relative molecular mass were analyzed by SDS-PAGE method; BCA assay was used to detect the level of protein; the immune activity of the recombinant protein was detected by immune inoculation method.40 mice were divided into rIsdB+adjuvant group(n=10), HBc-IsdB_50-285+adjuvant group(n=10), HBc-IsdB_50-285 group(n=10), and PBS group(n=10).The values of special IgG of the mice were tested by ELISA method. The mice were immunized and attacked by Stathylococcus aureus Newman strain,and the immune protection rate of the recombinant protein was detected.Results The expression vector pET-28-HBc-IsdB_50-285 was successfully constructed through identification of sequencing and restriction enzyme digestion. The SDS-PAGE results showed that the recombinant protein existed in a soluble form in the supernatant with relative molecular mass about 44 000.The level of purificated protein was 1.0 g·L^-1.The ELISA results showed that the value of antibody titer of the mice in HBc-IsdB_50-285+adjuvant group was lower than that in rIsdB+adjuvant group when the rIsdB were regarded as coating antigen(P<0.01);the values of antibody titer of the mice in HBc-IsdB_50-285+adjuvant group was higer than those in rIsdB+adjuvant group and HBc-IsdB_50-285 group when the HBc-IsdB_50-285 were regarded as coating antigen(P<0.05);the attack test results showed that the protection rate of Staphylococcus aureus of the mice in HBC-IsdB_50-285+adjuvant group was lower than that in rIsdB+adjuvant group (P>0.05). Compared with HBc-IsdB_50-285 group, the protection rate of Staphylococcus aureus of the mice in HBC-IsdB_50-285+adjuvant group had no significant difference (P>0.05). Compared with PBS group, the protection rates of Staphylococcus aureus of the mice in HBc-IsdB50-285+adjuvant group(P<0.01) and HBc-IsdB_50-285 group(P<0.05) were increased.Conclusion A prokaryotic expression vector of HBC-IsdB_50-285 is constructed, and the HBC-IsdB_50-285 fusion protein with better biological activities is expressed in E.coli BL21 successfully.

Key words: Staphylococcus aureus, hepatitis B virus core protein, iron-regulated surface determinant B, epitope

中图分类号:

R378.1

白靓, 成岩, 徐芳菲, 刘燕, 张树军, 曹瑞珍. 金黄色葡萄球菌IsdB表位蛋白与HBc蛋白融合表达[J]. 吉林大学学报(医学版), 2015, 41(02): 269-274.

BAI Liang, CHENG Yan, XU Fangfei, LIU Yan, ZHANG Shujun, CAO Ruizhen. Fusion expression of Staphylococcus aureus IsdB epitope protein and HBc protein[J]. Journal of Jilin University Medicine Edition, 2015, 41(02): 269-274.

参考文献

[1] Fowler VG Jr, Miro JM, Hoen B, et al. Staphylococcus aureus endocarditis:a consequence of medical progress[J]. JAMA, 2005, 293(24):3012-3021.

[2] Klevens RM,Morrison MA, Nadle J, et al.Invasive methicillin-resistant Staphylococcus aureus infections in the United States[J].J Am Med Assoc,2007,298(15):1763-1771.

[3] Mazmanian SK, Skaar EP, Gaspar AH, et al. Passage of heme-iron across the envelope of Staphylococcus aureus[J]. Science,2003, 299(5608):906-909.

[4] Brown M, Kowalski R, Zorman J, et al. Selection and characterization of murine monoclonal antibodies to Staphylococcus aureus iron-regulated surface determinant B with functional activity in vitro and in vivo[J]. Clin Vaccine Immunol,2009, 16(8):1095-1104.

[5] Ebert T, Smith S, Pancari G, et al. A fully human monoclonal antibody to Staphylococcus aureus iron regulated surface determinant B (IsdB) with functional activity in vitro and in vivo[J]. Hum Antibodies, 2010, 19(4):113-128.

[6] Schodel F, Moriarty AM, Peterson DL, et al. The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity[J]. J Virol,1992, 66(1):106-114.

[7] Roose K, De Baets S, Schepens B, et al. Hepatitis B core-based virus-like particles to present heterologous epitopes[J]. Expert Rev Vaccines, 2013, 12(2):183-198.

[8] 张占东, 徐静, 张云涛, 等. HBcAg-VEGF抗原表位融合蛋白的原核表达、纯化及其免疫原性[J]. 中国生物制品学杂志, 2013, 26(9):1278-1284.

[9] Yin Y, Zhang J, Chen W, et al. Chimeric hepatitis B virus core particles carrying an epitope of anthrax protective antigen induce protective immunity against Bacillus anthracis[J]. Vaccine, 2008,26(46):5814-5821.

[10] Yin Y, Zhang S, Chen W, et al. Deletion modification enhances anthrax specific immunity and protective efficacy of a hepatitis B core particle-based anthrax epitope vaccine[J]. Immunobiology, 2014, 219(2):97-103.

[11] Stranger-Jones YK, Bae T, Schneewind O, et al, Vaccine assembly from surface proteins of Staphylococcus aureus[J]. Proc Natl Acad Sci USA,2006, 103(45):16942-16947.

[12] Botelho-Nevers E, Verhoeven P, Paul S, et al. Staphylococcal vaccine development:review of past failures and plea for a future evaluation of vaccine efficacy not only on staphylococcal infections but also on mucosal carriage[J]. Expert Rev Vaccines, 2013, 12(11):1249-1259.

[13] Etz H, Minh DB, Henics T, et al. Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus[J]. Proc Natl Acad Sci USA,2002, 99(10):6573-6578.

[14] Spellberg B, Daum R. Development of a vaccine against Staphylococcus aureus[J]. Semin Immunopathol,2012, 34(2):335-348.

[15] Bottcher B, Wynne SA, Crowther RA, et al. Determination of the fold of the core protein of hepatitis B virus by electron cryomicroscopy[J]. Nature, 1997, 386(6620):88-91.

[16] Kratz PA, Bottcher B, Nassal M. Native display of complete foreign protein domains on the surface of hepatitis B virus capsids[J]. Proc Natl Acad Sci USA,1999, 96(5):1915-1920.

[17] Block H, Kubicek J, Labahn J, et al.Production and comprehensive quality control of recombinant human interleukin-1beta:a case study for a process development strategy[J].Protein Expr Purif, 2008, 57(2):244-254.

金黄色葡萄球菌IsdB表位蛋白与HBc蛋白融合表达

Fusion expression of Staphylococcus aureus IsdB epitope protein and HBc protein

RichHTML

PDF (PC)

赞

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 9

Metrics

本文评价

推荐阅读 0

[1]	王俊瑞, 段美庆, 额尔德木图, 孙鹏, 魏常梅, 韩艳秋. 亚抑菌浓度亚胺培南对MRSA体外增殖及毒力相关基因mRNA表达水平的影响[J]. 吉林大学学报(医学版), 2017, 43(03): 479-484.
[2]	辛桂杰, 朱海超, 李昊, 温剑平. 最低限度免疫定义基因表达的HCV多表位DNA疫苗对小鼠细胞免疫的诱导作用[J]. 吉林大学学报(医学版), 2016, 42(06): 1071-1075.
[3]	. 银杏叶提取物对牙龈卟啉单胞菌的体外抑菌作用[J]. 吉林大学学报(医学版), 2014, 40(05): 1018-1023.
[4]	杨思睿, 翟淑波, 吴秀丽, 于永利, 王丽颖. 沙眼衣原体T细胞表位融合蛋白对沙眼衣原体感染小鼠的保护机制[J]. J4, 2010, 36(5): 887-890.
[5]	张林波, 王海燕, 刘香英, 张丹丹, 刘英嘉, 温得中. 结核分枝杆菌抗原模拟表位肽的筛选及免疫活性鉴定[J]. J4, 2009, 35(4): 664-668.
[6]	王艳姝,田亚萍,万敏，于永利，王丽颖. 重组人乳头瘤病毒CTL表位疫苗的构建与表达[J]. J4, 2007, 33(2): 260-264.
[7]	李玉琴，谭岩，李树蕾，刘力华，段秀梅，方艳秋，许淑芬. 构建人肝细胞癌相关抗原HCA661和mtHSP70刺激表位的融合基因疫苗[J]. J4, 2007, 33(2): 373-376.
[8]	李丹，谭岩，刘力华，段秀梅，方艳秋，许淑芬，华树成. CEA迷你基因串联体肿瘤疫苗的构建[J]. J4, 2007, 33(2): 377-380.
[9]	杨思睿，卫红飞，孙景辉，杨煜，王燕媚，鲁继荣，于永利，王丽颖. HSP-沙眼衣原体MOMP T细胞表位基因的重组、原核表达和蛋白质纯化[J]. J4, 2006, 32(1): 11-4.